Clinical Trial Update: Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating caldonirimab plus nimotuzumab for recurrent or metastatic cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• caldonirimab (caldonirimab)

Snippet

Sponsor: Xi'an Jiaotong University | Conditions: Cervical Cancer | Phase 2 | Status: UNKNOWN